Non-contrast MRI can accurately characterize adnexal masses: a retrospective study.
Diagnosis
Magnetic resonance imaging
Ovarian cancer
Sensitivity and specificity
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
03
12
2020
accepted:
01
02
2021
pubmed:
17
3
2021
medline:
25
8
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
To determine the accuracy of interpretation of a non-contrast MRI protocol in characterizing adnexal masses. Two hundred ninety-one patients (350 adnexal masses) who underwent gynecological MRI at our institution between the 1 There were 53/350 (15.1%) malignant lesions in the whole cohort and 20/121 (16.5%) malignant lesions in the random subset. Good agreement between readers was found for the non-contrast MRI score (к = 0.73, 95% confidence interval [CI] 0.58-0.86) whilst the intra-reader agreement was excellent (к = 0.81, 95% CI 0.70-0.88). The non-contrast MRI score value of ≥ 4 was associated with malignancy with a sensitivity of 84.9%, a specificity of 95.9%, an accuracy of 94.2% and a positive likelihood ratio of 21 (area under the receiver operating curve 0.93, 95% CI 0.90-0.96). Adnexal mass characterization on MRI without the administration of contrast medium has a high accuracy and excellent inter- and intra-reader agreement. Our results suggest that non-contrast studies may offer a reasonable diagnostic alternative when the administration of intravenous contrast medium is not possible. • A non-contrast pelvic MRI protocol may allow the characterization of adnexal masses with high accuracy. • The non-contrast MRI score may be used in clinical practice for differentiating benign from malignant adnexal lesions when the lack of intravenous contrast medium precludes analysis with the O-RADS MRI score.
Identifiants
pubmed: 33725187
doi: 10.1007/s00330-021-07737-9
pii: 10.1007/s00330-021-07737-9
pmc: PMC8379126
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6962-6973Subventions
Organisme : Mark Foundation For Cancer Research
ID : C9685/A25177
Informations de copyright
© 2021. The Author(s).
Références
Timmerman D, Schwarzler P, Collins WP et al (1999) Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 13:11–16
doi: 10.1046/j.1469-0705.1999.13010011.x
Forstner R, Meissnitzer M, Cunha TM (2016) Update on imaging of ovarian cancer. Curr Radiol Rep 4:31
doi: 10.1007/s40134-016-0157-9
Sadowski EA, Rockall AG, Maturen KE, Robbins JB, Thomassin-Naggara I (2019) Adnexal lesions: imaging strategies for ultrasound and MR imaging. Diagn Interv Imaging 100:635–646
doi: 10.1016/j.diii.2018.06.003
Expert Panel on Women’s Imaging, Atri M, Alabousi A, Reinhold C et al (2019) ACR Appropriateness Criteria® Clinically suspected adnexal mass, no acute symptoms. J Am Coll Radiol 16(5S):S77–S93
Anthoulakis C, Nikoloudis N (2014) Pelvic MRI as the “gold standard” in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review. Gynecol Oncol 132:661–668
doi: 10.1016/j.ygyno.2013.10.022
Forstner R, Thomassin-Naggara I, Cunha TM et al (2017) ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol 27:2248–2257
doi: 10.1007/s00330-016-4600-3
Bazot M, Daraï E, Nassar-Slaba J, Lafont C, Thomassin-Naggara I (2008) Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr 32:712–723
doi: 10.1097/RCT.0b013e31815881ef
Medeiros LR, Freitas LB, Rosa DD et al (2011) Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. Am J Obstet Gynecol 204:67.e1–67.10
doi: 10.1016/j.ajog.2010.08.031
Allen BC, Hosseinzadeh K, Qasem SA, Varner A, Leyendecker JR (2014) Practical approach to MRI of female pelvic masses. AJR Am J Roentgenol 202:1366–1375
doi: 10.2214/AJR.13.12023
Thomassin-Naggara I, Aubert E, Rockall A et al (2013) Adnexal masses: development and preliminary validation of an MR imaging scoring system. Radiology 267:432–443
doi: 10.1148/radiol.13121161
Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A et al (2020) Ovarian-adnexal reporting data system magnetic resonance imaging (O-RADS MRI) score for risk stratification of sonographically indeterminate adnexal masses. JAMA Netw Open 3:e1919896
doi: 10.1001/jamanetworkopen.2019.19896
American College of Radiology (ACR) (2020) Ovarian-Adnexal Reporting and Data System (O–RADS). American College of Radiology (ACR) Web site. Available via https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/O-Rads#MRI . Accessed 6 June 2020
Pereira PN, Sarian LO, Yoshida A et al (2018) Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses. Diagn Interv Radiol 24:63–71
pubmed: 29467113
pmcid: 5873504
Pereira PN, Sarian LO, Yoshida A et al (2019) Improving the performance of IOTA simple rules: sonographic assessment of adnexal masses with resource-effective use of a magnetic resonance scoring (ADNEX MR scoring system). Abdom Radiol (NY). https://doi.org/10.1007/s00261-019-02207-9
Ramalho J, Ramalho M, Jay M, Burke LM, Semelka RC (2016) Gadolinium toxicity and treatment. Magn Reson Imaging 34:1394–1398
doi: 10.1016/j.mri.2016.09.005
The Royal College of Radiologists (2018) RCR position statement on the revision of marketing authorisations for gadolinium based contrast agents. Available via https://www.rcr.ac.uk/posts/rcr-position-statement-revision-marketing-authorisations-gadolinium-based-contrast-agents . Accessed 26 March 2020
The Royal College of Radiologists (2019). Guidance on gadolinium-based contrast agent administration to adult patients. Available via https://www.rcr.ac.uk/publication/guidance-gadolinium-based-contrast-agent-administration-adult-patients . Accessed 26 March 2020
Andreotti RF, Timmerman D, Benacerraf BR et al (2018) Ovarian-Adnexal reporting lexicon for ultrasound: a white paper of the ACR Ovarian-Adnexal Reporting and Data System Committee. J Am Coll Radiol 15:1415–1429
doi: 10.1016/j.jacr.2018.07.004
Tong A (2020) Differentiating benign and malignant adnexal masses: work still in progress. Diagn Interv Imaging 101:127–128
doi: 10.1016/j.diii.2020.02.008
Timmerman D, Testa AC, Bourne T et al (2005) Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 23:8794–8801
doi: 10.1200/JCO.2005.01.7632
Rossi A, Braghin C, Soldano F et al (2011) A proposal for a new scoring system to evaluate pelvic masses: Pelvic Masses Score (PMS). Eur J Obstet Gynecol Reprod Biol 157:84–88
doi: 10.1016/j.ejogrb.2011.02.009
Meys EM, Kaijser J, Kruitwagen RF et al (2016) Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 58:17–29
doi: 10.1016/j.ejca.2016.01.007
Sadowski EA, Robbins JB, Rockall AG, Thomassin-Naggara I (2018) A systematic approach to adnexal masses discovered on ultrasound: the ADNEx MR scoring system. Abdom Radiol (NY) 43:679–695
doi: 10.1007/s00261-017-1272-7
Ruiz M, Labauge P, Louboutin A, Limot O, Fauconnier A, Huchon C (2016) External validation of the MR imaging scoring system for the management of adnexal masses. Eur J Obstet Gynecol Reprod Biol 205:115–119
doi: 10.1016/j.ejogrb.2016.07.493
Sasaguri K, Yamaguchi K, Nakazono T et al (2019) External validation of ADNEX MR SCORING system: a single-centre retrospective study. Clin Radiol 74:131–139
doi: 10.1016/j.crad.2018.10.014
Miramura R, Kato F, Tha KK et al (2016) Comparison between borderline ovarian tumors and carcinomas using semi-automated histogram analysis of diffusion-weighted imaging: focusing on solid components. Jpn J Radiol 34:229–237
doi: 10.1007/s11604-016-0518-6
Lu JJ, Pi S, Ma FH, Zhang GF, Wei Qiang J (2019) Apparent diffusion coefficients measured using different regions of interest in differentiating borderline from malignant ovarian tumors. Acta Radiol 60:1020–1027
doi: 10.1177/0284185118805272
Lu J, Pi S, Ma FH et al (2019) Value of normalized apparent diffusion coefficients in differentiating between borderline and malignant epithelial ovarian tumors. Eur J Radiol 118:44–50
doi: 10.1016/j.ejrad.2019.06.020
He M, Song Y, Li H et al (2020) Histogram analysis comparison of monoexponential advanced diffusion-weighted imaging, and dynamic contrast-enhanced MRI for differentiating borderline from malignant epithelial ovarian tumors. J Magn Reson Imaging 52:257–268
doi: 10.1002/jmri.27037
Schieda N, Krishna S, Davenport MS (2019) Update on Gadolinium-based contrast agent-enhanced imaging in the genitourinary system. AJR Am J Roentgenol 11:1–11